BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2018;47:16-25. [DOI: 10.1111/apt.14401] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 165] [Cited by in F6Publishing: 164] [Article Influence: 55.0] [Reference Citation Analysis]
2 Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, Pareja MJ, Vilar-Gómez E, Caballería J, Escudero-García D, Gomez-Camarero J, Calleja JL, Latorre M, Albillos A, Salmeron J, Aspichueta P, Lo Iacono O, Francés R, Benlloch S, Fernández-Rodríguez C, García-Samaniego J, Estévez P, Andrade RJ, Turnes J, Romero-Gómez M; HEPAmet Registry. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther 2018;48:1260-70. [PMID: 30353552 DOI: 10.1111/apt.15015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
3 Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, Strasser M, Huber-Schönauer U, Buch S, Hampe J, Paulweber B, Lackner C, Haufe H, Sotlar K, Datz C, Aigner E. Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients. J Clin Med 2018;7:E562. [PMID: 30562976 DOI: 10.3390/jcm7120562] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
4 Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36:1497-507. [PMID: 33217052 DOI: 10.1111/jgh.15353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
6 Wong WK, Chan WK. Nonalcoholic Fatty Liver Disease: A Global Perspective. Clin Ther 2021;43:473-99. [PMID: 33526312 DOI: 10.1016/j.clinthera.2021.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
7 Kang SY, Kim YJ, Park HS. Trends in the Prevalence of Non-Alcoholic Fatty Liver Disease and Its Future Predictions in Korean Men, 1998-2035. J Clin Med 2020;9:E2626. [PMID: 32823604 DOI: 10.3390/jcm9082626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Leung JC, Wong VW. Editorial: non-alcoholic fatty liver disease-it is better to be slender after all. Aliment Pharmacol Ther 2018;47:305-6. [PMID: 29265466 DOI: 10.1111/apt.14432] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Buzova D, Maugeri A, Liguori A, Napodano C, Lo Re O, Oben J, Alisi A, Gasbarrini A, Grieco A, Cerveny J, Miele L, Vinciguerra M. Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). Clin Epigenetics 2020;12:126. [PMID: 32819448 DOI: 10.1186/s13148-020-00917-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Shaunak M, Byrne CD, Davis N, Afolabi P, Faust SN, Davies JH. Non-alcoholic fatty liver disease and childhood obesity.Arch Dis Child. 2021;106:3-8. [PMID: 32409495 DOI: 10.1136/archdischild-2019-318063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
11 Koo DJ, Lee MY, Jung I, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. PLoS One 2021;16:e0255535. [PMID: 34432804 DOI: 10.1371/journal.pone.0255535] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jung Y, Lee MK, Puri P, Koo BK, Joo SK, Jang SY, Lee DH, Jung YJ, Kim BG, Lee KL, Park TS, Kang KT, Ryu DH, Kang SW, Kim D, Oh S, Kim W, Hwang GS. Circulating lipidomic alterations in obese and non-obese subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;52:1603-14. [PMID: 32892365 DOI: 10.1111/apt.16066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Sookoian S, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycoechea M, Pirola CJ. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 2020;69:1483-91. [DOI: 10.1136/gutjnl-2019-318811] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 17.5] [Reference Citation Analysis]
14 Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00112. [PMID: 33102794 DOI: 10.1002/edm2.112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
15 Khayyat YM. Lean non-alcoholic fatty liver disease and associated metabolic disturbance: A Saudi Arabian cross-sectional study. Physiol Rep 2021;9:e14949. [PMID: 34278728 DOI: 10.14814/phy2.14949] [Reference Citation Analysis]
16 Kuo Y, Kee K, Wang J, Hsu N, Hsiao C, Chen Y, Lu S. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. Aliment Pharmacol Ther 2018;48:993-1002. [DOI: 10.1111/apt.14960] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
17 Lu CW, Lee YC, Chiang CH, Chang HH, Yang WS, Huang KC. Independent Dose-Response Associations between Fetuin-A and Lean Nonalcoholic Fatty Liver Disease. Nutrients 2021;13:2928. [PMID: 34578806 DOI: 10.3390/nu13092928] [Reference Citation Analysis]
18 Tirosh O. Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression. Oxid Med Cell Longev 2018;2018:2548154. [PMID: 29955245 DOI: 10.1155/2018/2548154] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
19 Chung GE, Heo NJ, Kim D, Kwak MS, Yim JY, Kim JS, Ahmed A. Association between advanced fibrosis in fatty liver disease and overall mortality based on body fat distribution. J Gastroenterol Hepatol 2020;35:90-6. [PMID: 31272131 DOI: 10.1111/jgh.14778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Dong BY, Mao YQ, Li ZY, Yu FJ. The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study. Lipids Health Dis 2020;19:148. [PMID: 32576204 DOI: 10.1186/s12944-020-01319-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ariya M, Koohpayeh F, Ghaemi A, Osati S, Davoodi SH, Razzaz JM, Javedan G, Ehrampoush E, Homayounfar R. Assessment of the association between body composition and risk of non-alcoholic fatty liver. PLoS One 2021;16:e0249223. [PMID: 33793621 DOI: 10.1371/journal.pone.0249223] [Reference Citation Analysis]
22 Shao C, Ye J, Li F, Lin Y, Wu T, Wang W, Feng S, Zhong B. Early Predictors of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease: Non-obese Versus Obese Patients. Dig Dis Sci. 2020;65:1850-1860. [PMID: 31724099 DOI: 10.1007/s10620-019-05926-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
23 Wong VW, Wong GL, Chan RS, Shu SS, Cheung BH, Li LS, Chim AM, Chan CK, Leung JK, Chu WC, Woo J, Chan HL. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69:1349-1356. [PMID: 30142427 DOI: 10.1016/j.jhep.2018.08.011] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
24 Pirola CJ, Sookoian S. Epigenetics factors in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2020.1765772] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 De Vincentis A, Tavaglione F, Spagnuolo R, Pujia R, Tuccinardi D, Mascianà G, Picardi A, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. Int J Obes (Lond) 2021. [PMID: 34750514 DOI: 10.1038/s41366-021-01015-w] [Reference Citation Analysis]
26 Shao C, Ye J, Li F, Feng S, Wang W, Zhong B. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Digestive and Liver Disease 2019;51:1392-9. [DOI: 10.1016/j.dld.2019.02.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Kalogirou MS, Patoulias D, Haidich AB, Akriviadis E, Sinakos E. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2021;45:101568. [PMID: 33309563 DOI: 10.1016/j.clinre.2020.10.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Zou ZY, Wong VW, Fan JG. Epidemiology of nonalcoholic fatty liver disease in non‐obese populations: Meta‐analytic assessment of its prevalence, genetic, metabolic, and histological profiles. J Dig Dis 2020;21:372-84. [DOI: 10.1111/1751-2980.12871] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
29 Ding L, Oligschlaeger Y, Shiri-Sverdlov R, Houben T. Nonalcoholic Fatty Liver Disease. Handb Exp Pharmacol 2020. [PMID: 32185502 DOI: 10.1007/164_2020_352] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389-398. [PMID: 30902670 DOI: 10.1016/s2468-1253(19)30039-1] [Cited by in Crossref: 165] [Cited by in F6Publishing: 94] [Article Influence: 55.0] [Reference Citation Analysis]
31 Chamulitrat W, Jansakun C, Li H, Liebisch G. Rescue of Hepatic Phospholipid Remodeling Defectin iPLA2β-Null Mice Attenuates Obese but Not Non-Obese Fatty Liver. Biomolecules 2020;10:E1332. [PMID: 32957701 DOI: 10.3390/biom10091332] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
32 Shi YW, He FP, Chen JJ, Deng H, Shi JP, Zhao CY, Mi YQ, Zou ZS, Zhou YJ, Di FS, Zheng RD, Du Q, Shang J, Yang RX, Popovic B, Zhong BH, Fan JG. Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol 2021;9:607-14. [PMID: 34722175 DOI: 10.14218/JCTH.2021.00058] [Reference Citation Analysis]
33 Jung CH, Rhee EJ, Kwon H, Chang Y, Ryu S, Lee WY. Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis. Endocrinol Metab (Seoul) 2020;35:165-76. [PMID: 32207277 DOI: 10.3803/EnM.2020.35.1.165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
34 Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2019;17:543-550.e2. [PMID: 30012432 DOI: 10.1016/j.cgh.2018.07.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]